Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KYNTRA BIO, INC.FGEN · Entity 7431 | Director · Chief Executive Officer | August 21, 2019 | August 23, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KYNTRA BIO, INC.
Report date August 21, 2019 · Filed August 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,326,612 |
Ending reported balance
After 2019-08-22 transaction · row 6
5 source rows · reconciled sequenceRow 1 · 2019-08-21 · Exercise / conversion · Acquired 6,834 · Balance 2,356,578 Row 2 · 2019-08-21 · Sale · Disposed 18,400 · Balance 2,338,178 F1: Shares sold pursuant to a 10b5-1 plan. F2: The shares were sold at prices ranging from $44.54 to $45.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 4 · 2019-08-22 · Exercise / conversion · Acquired 6,834 · Balance 2,345,012 Row 5 · 2019-08-22 · Sale · Disposed 17,100 · Balance 2,327,912 F1: Shares sold pursuant to a 10b5-1 plan. F4: The shares were sold at prices ranging from $43.46 to $44.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 6 · 2019-08-22 · Sale · Disposed 1,300 · Balance 2,326,612 F1: Shares sold pursuant to a 10b5-1 plan. F5: The shares were sold at prices ranging from $44.61 to $44.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Partnership | 45,656 |
Reported balance
After 2019-08-21 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2019-08-21 · Sale · Disposed 1,418 · Balance 45,656 F1: Shares sold pursuant to a 10b5-1 plan. F3: The shares were sold at prices ranging from $44.51 to $45.115. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Partnership | 44,238 |
Reported balance
After 2019-08-22 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2019-08-22 · Sale · Disposed 1,418 · Balance 44,238 F1: Shares sold pursuant to a 10b5-1 plan. F6: The shares were sold at prices ranging from $43.47 to $43.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2020-06-09 | Direct | 184,536 |
Reported balance
After 2019-08-21 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-08-21 · Exercise / conversion · Disposed 6,834 · Balance 184,536 F8: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2020-06-09 | Direct | 177,702 |
Reported balance
After 2019-08-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-08-22 · Exercise / conversion · Disposed 6,834 · Balance 177,702 F8: Fully vested. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 20,000 |
Reported balance
Holding disclosure · report date 2019-08-21 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 20,000 |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 60,946 |
Reported balance
Holding disclosure · report date 2019-08-21 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 60,946 F7: The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a 10b5-1 plan.
F2: The shares were sold at prices ranging from $44.54 to $45.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: The shares were sold at prices ranging from $44.51 to $45.115. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: The shares were sold at prices ranging from $43.46 to $44.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5: The shares were sold at prices ranging from $44.61 to $44.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6: The shares were sold at prices ranging from $43.47 to $43.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7: The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.
F8: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 12, 2017 Filed Apr 14, 2017 22:06 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $24.57 | $10,270.26 |
DisclosureSEC source: 0001209191-17-026994 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 141,308 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $24.50 to $24.65. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 12, 2017 Filed Apr 14, 2017 22:06 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,300 | $25.28 | $58,144.00 |
DisclosureSEC source: 0001209191-17-026994 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,327,041 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $25.00 to $25.55. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 12, 2017 Filed Apr 14, 2017 22:06 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 16,600 | $24.58 | $408,028.00 |
DisclosureSEC source: 0001209191-17-026994 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,329,341 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $24.25 to $24.975. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 12, 2017 Filed Apr 14, 2017 22:06 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 18,900 | $4.03 | $76,072.50 |
DisclosureSEC source: 0001209191-17-026994 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,345,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2017 Filed Apr 5, 2017 01:39 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,900 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001209191-17-025427 · doc4.xml · derivative · entry 10 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,494 Underlying: Common Stock · 18,900 shares Expires 2017-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| April 04, 2017 Filed Apr 5, 2017 01:39 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $23.80 | $9,948.40 |
DisclosureSEC source: 0001209191-17-025427 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 141,726 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $23.70 to $24.00. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 04, 2017 Filed Apr 5, 2017 01:39 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,900 | $23.85 | $450,765.00 |
DisclosureSEC source: 0001209191-17-025427 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,327,041 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $23.60 to $24.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 04, 2017 Filed Apr 5, 2017 01:39 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 18,900 | $4.03 | $76,072.50 |
DisclosureSEC source: 0001209191-17-025427 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,345,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 01:39 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Options (Right to Buy) · Derivative | 18,900 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001209191-17-025427 · doc4.xml · derivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,394 Underlying: Common Stock · 18,900 shares Expires 2017-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 01:39 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $23.92 | $9,998.56 |
DisclosureSEC source: 0001209191-17-025427 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 142,144 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $23.70 to $24.20. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 01:39 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,900 | $23.99 | $453,411.00 |
DisclosureSEC source: 0001209191-17-025427 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,327,041 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $23.60 to $24.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 01:39 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 18,900 | $4.03 | $76,072.50 |
DisclosureSEC source: 0001209191-17-025427 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,345,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 21, 2017 Filed Mar 22, 2017 22:36 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,900 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001209191-17-022419 · doc4.xml · derivative · entry 12 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,294 Underlying: Common Stock · 18,900 shares Expires 2017-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| March 21, 2017 Filed Mar 22, 2017 22:36 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $23.58 | $9,856.44 |
DisclosureSEC source: 0001209191-17-022419 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 142,562 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $23.10 to $24.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 21, 2017 Filed Mar 22, 2017 22:36 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 400 | $25.06 | $10,024.00 |
DisclosureSEC source: 0001209191-17-022419 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,327,041 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $25.00 to $25.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 21, 2017 Filed Mar 22, 2017 22:36 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 4,700 | $24.54 | $115,338.00 |
DisclosureSEC source: 0001209191-17-022419 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,327,441 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $24.00 to $24.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 21, 2017 Filed Mar 22, 2017 22:36 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 13,800 | $23.51 | $324,438.00 |
DisclosureSEC source: 0001209191-17-022419 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,332,141 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $23.10 to $23.90. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 21, 2017 Filed Mar 22, 2017 22:36 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 18,900 | $4.03 | $76,072.50 |
DisclosureSEC source: 0001209191-17-022419 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,345,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 22:36 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Options (Right to Buy) · Derivative | 18,900 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001209191-17-022419 · doc4.xml · derivative · entry 11 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,194 Underlying: Common Stock · 18,900 shares Expires 2017-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 22:36 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $24.92 | $10,416.56 |
DisclosureSEC source: 0001209191-17-022419 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 142,980 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $24.80 to $25.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 22:36 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,900 | $24.88 | $470,232.00 |
DisclosureSEC source: 0001209191-17-022419 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,327,041 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $24.55 to $25.08. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 22:36 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 18,900 | $4.03 | $76,072.50 |
DisclosureSEC source: 0001209191-17-022419 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,345,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2017 Filed Mar 16, 2017 23:29 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,858 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001209191-17-021206 · doc4.xml · derivative · entry 11 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,094 Underlying: Common Stock · 10,858 shares Expires 2017-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| March 15, 2017 Filed Mar 16, 2017 23:29 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $25.26 | $10,558.68 |
DisclosureSEC source: 0001209191-17-021206 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,398 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $25.10 to $25.375. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 15, 2017 Filed Mar 16, 2017 23:29 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,900 | $25.07 | $473,823.00 |
DisclosureSEC source: 0001209191-17-021206 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,327,041 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $24.55 to $25.45. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 15, 2017 Filed Mar 16, 2017 23:29 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,858 | $4.03 | $43,703.45 |
DisclosureSEC source: 0001209191-17-021206 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,345,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 23:29 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,858 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001209191-17-021206 · doc4.xml · derivative · entry 10 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,952 Underlying: Common Stock · 10,858 shares Expires 2017-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 23:29 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $25.02 | $10,458.36 |
DisclosureSEC source: 0001209191-17-021206 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 143,816 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $24.75 to $25.25. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 23:29 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 500 | $25.79 | $12,895.00 |
DisclosureSEC source: 0001209191-17-021206 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,335,083 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $25.70 to $25.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 23:29 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,400 | $25.04 | $460,736.00 |
DisclosureSEC source: 0001209191-17-021206 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,335,583 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $24.70 to $25.65. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 23:29 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,858 | $4.03 | $43,703.45 |
DisclosureSEC source: 0001209191-17-021206 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,353,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2017 Filed Mar 9, 2017 01:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 172,800 | $0.00 Strike: $25.40 | $0.00 |
DisclosureSEC source: 0001209191-17-019466 · doc4.xml · derivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,800 Underlying: Common Stock · 172,800 shares Expires 2027-03-08 F4 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on March 1, 2018, and the remainder vests in equal amounts quarterly thereafter for the following three years. Read SEC document |
| March 08, 2017 Filed Mar 9, 2017 01:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 105,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-019466 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,343,125 F2 · shares: Represents the grant of restricted stock units. Twenty-five percent of the restricted stock units vest on March 6, 2018, and the remainder vests in equal amounts quarterly thereafter for the following three years. Read SEC document |
| March 06, 2017 Filed Mar 9, 2017 01:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 17,736 | $25.35 | $449,607.60 |
DisclosureSEC source: 0001209191-17-019466 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,237,425 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 00:59 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,900 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001209191-17-011303 · doc4.xml · derivative · entry 10 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,810 Underlying: Common Stock · 18,900 shares Expires 2017-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 00:59 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $23.89 | $9,986.02 |
DisclosureSEC source: 0001209191-17-011303 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 144,234 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $23.625 to $24.20. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 00:59 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,900 | $23.90 | $451,710.00 |
DisclosureSEC source: 0001209191-17-011303 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,255,161 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $23.60 to $24.225. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 00:59 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 18,900 | $4.03 | $76,072.50 |
DisclosureSEC source: 0001209191-17-011303 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,274,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2017 Filed Feb 16, 2017 00:59 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,900 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001209191-17-011303 · doc4.xml · derivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,710 Underlying: Common Stock · 18,900 shares Expires 2017-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| February 13, 2017 Filed Feb 16, 2017 00:59 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 418 | $24.01 | $10,036.18 |
DisclosureSEC source: 0001209191-17-011303 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 144,652 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $23.90 to $24.20. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 13, 2017 Filed Feb 16, 2017 00:59 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,900 | $23.97 | $453,033.00 |
DisclosureSEC source: 0001209191-17-011303 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,255,161 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $23.70 to $24.25. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 13, 2017 Filed Feb 16, 2017 00:59 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 18,900 | $4.03 | $76,072.50 |
DisclosureSEC source: 0001209191-17-011303 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,274,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2017 Filed Feb 11, 2017 00:24 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,091 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001209191-17-009779 · doc4.xml · derivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,610 Underlying: Common Stock · 14,091 shares Expires 2017-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| February 09, 2017 Filed Feb 11, 2017 00:24 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,899 | $23.89 | $451,497.11 |
DisclosureSEC source: 0001209191-17-009779 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,255,161 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $23.55 to $24.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2017 Filed Feb 11, 2017 00:24 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 14,091 | $4.03 | $56,716.28 |
DisclosureSEC source: 0001209191-17-009779 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,274,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:24 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,091 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001209191-17-009779 · doc4.xml · derivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,701 Underlying: Common Stock · 14,091 shares Expires 2017-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:24 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,899 | $23.03 | $435,243.97 |
DisclosureSEC source: 0001209191-17-009779 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,259,969 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $22.70 to $23.55. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:24 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 14,091 | $4.03 | $56,716.28 |
DisclosureSEC source: 0001209191-17-009779 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,278,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2017 Filed Jan 27, 2017 23:50 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,091 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001209191-17-006048 · doc4.xml · derivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,792 Underlying: Common Stock · 14,091 shares Expires 2017-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| January 27, 2017 Filed Jan 27, 2017 23:50 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,899 | $23.16 | $437,700.84 |
DisclosureSEC source: 0001209191-17-006048 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,264,777 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $22.90 to $23.55. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.